Diakonos Oncology
Monday, February 26, 2024
Uris
Oncology
Clinical Efficacy in the Toughest Cancers -- Cracking the Code on Dendritic Cell Therapy and Tumor Infiltrating Lymphocytes
Diakonos Oncology is developing two cell therapy technologies developed at MD Anderson and Baylor College of Medicine. The seed-stage company is in a unique position due to early clinical progress achieved under an investigator sponsored protocol for the lead asset, DOC1021. The Phase 1 study in “moonshot” GBM patients is now fully enrolled (n=18) with topline data expected in 1H24. To date, interim median PFS is 9+ mo. (vs 4 mo. expected) and interim average survival for Cohort 1 (low dose, n=3) is 19.8+ mo. (vs 15 mo. expected).
Clinical benefits have been observed in multiple (10+) other cancer types in IST and IST-like settings (incl. 4/5 CRs in PDAC patients).
Fast Track & Orphan Drug Designation have been awarded for DOC1021 based on 1) observed survival benefit in GBM Phase 1 and 2) no attributable Serious Adverse Events (SAEs) to date.
State
Texas
Country
United States
Website
https://www.diakonosoncology.com/
CEO/Top Company Official
Mike Wicks
Lead Product in Development
DOC1021
Development Phase of Primary Product
Phase I
Number Of Unlicensed Products
3
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}